This poster presents key insights into global public and philanthropic investment in antibacterial research and development between 2017 and 2023, based on our recently published Lancet Microbe paper.
𝐖𝐡𝐚𝐭 𝐝𝐢𝐝 𝐰𝐞 𝐟𝐢𝐧𝐝?
- Investment peaked in 2020 and has since fallen by 18%
- $2.51 billion was invested by 130 funders, with funding highly concentrated among a few major players
- Early-research funding has declined, while clinical development remains relatively stable
- Funding broadly aligns with WHO priority pathogens, though some gaps remain
- Traditional approaches dominate, while many non-traditional strategies, like phages, peptides etc., struggle to translate
𝐖𝐡𝐲 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫𝐬
As private investment continues to shrink, antibacterial innovation increasingly relies on public funding, philanthropy, and partnerships
Initiatives such as Global Antibiotic R&D Partnership (GARDP) and CARB-X are essential – but they alone cannot sustain the system
𝐎𝐮𝐫 𝐭𝐚𝐤𝐞-𝐡𝐨𝐦𝐞 𝐦𝐞𝐬𝐬𝐚𝐠𝐞
Sustained investment is necessary, but stronger strategic alignment across funders, sectors, and R&D stages is essential to deliver new antibacterial medicines that meet priority public health needs
This work is the result of a close collaboration between Global Antibiotic R&D Partnership (GARDP) and the Global AMR R&D Hub.
